oxiracetam has been researched along with Amentia in 7 studies
oxiracetam: structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effectiveness of Oxiracetam (1600 mg/day) versus placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 9.07 | Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1993) |
| "The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 9.07 | Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1992) |
| "Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD)." | 9.06 | Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. ( Dysken, MW; Katz, R; Kuskowski, M; Stallone, F, 1989) |
| "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800-mg tablets), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed forms of dementia." | 9.06 | Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. ( Bonavita, E; Fagiani, MB; Ferrario, E; Fiori, L; Ghiazza, B; Maina, G; Ravizza, L; Teruzzi, F; Torta, R; Zagnoni, PG, 1989) |
| "40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment." | 9.06 | Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. ( Grioli, S; Lomeo, C; Parini, J; Quattropani, M; Scapagnini, U; Villardita, C, 1987) |
| "The effectiveness of Oxiracetam (1600 mg/day) versus placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 5.07 | Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1993) |
| "The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 5.07 | Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1992) |
| "Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD)." | 5.06 | Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. ( Dysken, MW; Katz, R; Kuskowski, M; Stallone, F, 1989) |
| "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800-mg tablets), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed forms of dementia." | 5.06 | Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. ( Bonavita, E; Fagiani, MB; Ferrario, E; Fiori, L; Ghiazza, B; Maina, G; Ravizza, L; Teruzzi, F; Torta, R; Zagnoni, PG, 1989) |
| "40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment." | 5.06 | Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. ( Grioli, S; Lomeo, C; Parini, J; Quattropani, M; Scapagnini, U; Villardita, C, 1987) |
| "Oxiracetam, a new substance found to be a nootropic in experimental pharmacological studies, was tested in three clinical trials: a single rising dose tolerance and dose-finding study with quantitative pharmaco-electroencephalogram (pharmaco-EEG) and quantitative pharmacopsychology in healthy volunteers; a dose-finding study, at three dose levels for 3 months, with quantitative pharmaco-EEG in mild to moderate dementia patients; and a safety and efficacy study with increasing dosages for 12 weeks with subjective and objective tests in elderly patients with dementia." | 3.67 | CNS pharmacology and clinical therapeutic effects of oxiracetam. ( Itil, KZ; Itil, TM; Menon, GN; Songar, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rozzini, R | 2 |
| Zanetti, O | 2 |
| Bianchetti, A | 2 |
| Dysken, MW | 1 |
| Katz, R | 1 |
| Stallone, F | 1 |
| Kuskowski, M | 1 |
| Gava, R | 1 |
| Schifano, F | 1 |
| Maina, G | 1 |
| Fiori, L | 1 |
| Torta, R | 1 |
| Fagiani, MB | 1 |
| Ravizza, L | 1 |
| Bonavita, E | 1 |
| Ghiazza, B | 1 |
| Teruzzi, F | 1 |
| Zagnoni, PG | 1 |
| Ferrario, E | 1 |
| Villardita, C | 1 |
| Parini, J | 1 |
| Grioli, S | 1 |
| Quattropani, M | 1 |
| Lomeo, C | 1 |
| Scapagnini, U | 1 |
| Itil, TM | 1 |
| Menon, GN | 1 |
| Songar, A | 1 |
| Itil, KZ | 1 |
1 review available for oxiracetam and Amentia
| Article | Year |
|---|---|
[Oxiracetam].
Topics: Adult; Aged; Animals; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia; Dogs; Humans; M | 1989 |
6 trials available for oxiracetam and Amentia
| Article | Year |
|---|---|
Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
Topics: Aged; Ambulatory Care; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Male; Neu | 1993 |
Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Male; N | 1992 |
Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Dementia; Dementia, Multi-Infarct; Dose-Respons | 1989 |
[Oxiracetam].
Topics: Adult; Aged; Animals; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia; Dogs; Humans; M | 1989 |
Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Dementia; Dementia, Multi-Infarct; Double-Blind Method; Female; Humans; Mal | 1989 |
Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
Topics: Aged; Cognition; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrrolidines | 1987 |
1 other study available for oxiracetam and Amentia
| Article | Year |
|---|---|
CNS pharmacology and clinical therapeutic effects of oxiracetam.
Topics: Brain; Dementia; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Electroencephal | 1986 |